Journal Home > Volume 16 , Issue 12
Nano Research 2023, 16(12): 13077-13099 https://doi.org/10.1007/s12274-023-6026-y
Review Article | Issue | Published: 12 October 2023

Intranasal administration nanosystems for brain-targeted drug delivery

Show Author's Information Yue Jiang1,2,  Xueting Pan1,  Tao Yu3( ),  Hai Wang1,2( )
CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China
University of Chinese Academy of Sciences, Beijing 100049, China
Beijing Institute of Functional Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
Keywords:
neurological diseases, drug delivery, intranasal administration, nanosystems, brain-targeted delivery
Topics:
Targeted drug delivery
Cite this article:
Jiang Y, Pan X, Yu T, et al. Intranasal administration nanosystems for brain-targeted drug delivery. Nano Research, 2023, 16(12): 13077-13099. https://doi.org/10.1007/s12274-023-6026-y
Download citation
EndNote(RIS)
BibTeX

597

Views

73

Downloads

Citations

1

Crossref

2

WoS

2

Scopus

0

CSCD

Abstract Full text About this article

The existence of the blood-brain barrier (BBB) restricts the entry of drugs from the circulation into the central nervous system (CNS), which severely affects the treatment of neurological diseases, including glioblastoma, Parkinson’s disease (PD), and Alzheimer’s disease (AD). With the advantage of bypassing the BBB and avoiding systemic distribution, intranasal administration has emerged as an alternative method of delivering drugs to the brain. Drug delivery directly to the brain using intranasal nanosystems represents a new paradigm for neurological disease treatment because of its advantages in improving drug solubility and stability in vivo, enabling targeted drug delivery and controlled release, and reducing non-specific toxicity. And it has shown efficacy in animal models and clinical applications. Herein, this review describes the mechanisms of intranasal delivery of brain-targeted drugs, the properties of nanosystems for intranasal administration (e.g., liposomes, nanoemulsions, and micelles), and strategies for intranasal drug delivery to enhance brain-targeted drug delivery. Recent applications of nanosystems in intranasal drug delivery and disease treatment have been comprehensively reviewed. Although encouraging results have been reported, significant challenges still need to be overcome to translate these nanosystems into clinics. Therefore, the future prospects of intranasal drug delivery nanosystems are discussed in depth, expecting to provide useful insights and guidance for effective neurological disease treatment.


menu
Abstract
Full text
Outline
About this article

Intranasal administration nanosystems for brain-targeted drug delivery

Show Author's information Yue Jiang1,2, Xueting Pan1, Tao Yu3( ), Hai Wang1,2( )
CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China
University of Chinese Academy of Sciences, Beijing 100049, China
Beijing Institute of Functional Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China

Abstract

The existence of the blood-brain barrier (BBB) restricts the entry of drugs from the circulation into the central nervous system (CNS), which severely affects the treatment of neurological diseases, including glioblastoma, Parkinson’s disease (PD), and Alzheimer’s disease (AD). With the advantage of bypassing the BBB and avoiding systemic distribution, intranasal administration has emerged as an alternative method of delivering drugs to the brain. Drug delivery directly to the brain using intranasal nanosystems represents a new paradigm for neurological disease treatment because of its advantages in improving drug solubility and stability in vivo, enabling targeted drug delivery and controlled release, and reducing non-specific toxicity. And it has shown efficacy in animal models and clinical applications. Herein, this review describes the mechanisms of intranasal delivery of brain-targeted drugs, the properties of nanosystems for intranasal administration (e.g., liposomes, nanoemulsions, and micelles), and strategies for intranasal drug delivery to enhance brain-targeted drug delivery. Recent applications of nanosystems in intranasal drug delivery and disease treatment have been comprehensively reviewed. Although encouraging results have been reported, significant challenges still need to be overcome to translate these nanosystems into clinics. Therefore, the future prospects of intranasal drug delivery nanosystems are discussed in depth, expecting to provide useful insights and guidance for effective neurological disease treatment.

Keywords: neurological diseases, drug delivery, intranasal administration, nanosystems, brain-targeted delivery

References(211)

[1]

D’Souza, A.; Dave, K. M.; Stetler, R. A.; Manickam, D. S. Targeting the blood-brain barrier for the delivery of stroke therapies. Adv. Drug Deliv. Rev. 2021, 171, 332–351.
DOI Google Scholar
[2]

Sweeney, M. D.; Zhao, Z.; Montagne, A.; Nelson, A. R.; Zlokovic, B. V. Blood-brain barrier: From physiology to disease and back. Physiol. Rev. 2019, 99, 21–78.
DOI Google Scholar
[3]

Banks, W. A. From blood-brain barrier to blood-brain interface: New opportunities for CNS drug delivery. Nat. Rev. Drug Discov. 2016, 15, 275–292.
DOI Google Scholar
[4]

Zhan, W. B.; Wang, C. H. Convection enhanced delivery of chemotherapeutic drugs into brain tumour. J. Control. Release 2018, 271, 74–87.
DOI Google Scholar
[5]

Bellat, V.; Alcaina, Y.; Tung, C. H.; Ting, R.; Michel, A. O.; Souweidane, M.; Law, B. A combined approach of convection-enhanced delivery of peptide nanofiber reservoir to prolong local DM1 retention for diffuse intrinsic pontine glioma treatment. Neuro Oncol. 2020, 22, 1495–1504.
DOI Google Scholar
[6]

Mangraviti, A.; Gullotti, D.; Tyler, B.; Brem, H. Nanobiotechnology-based delivery strategies: New frontiers in brain tumor targeted therapies. J. Control. Release 2016, 240, 443–453.
DOI Google Scholar
[7]

Tang, W.; Fan, W. P.; Lau, J.; Deng, L. M.; Shen, Z. Y.; Chen, X. Y. Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics. Chem. Soc. Rev. 2019, 48, 2967–3014.
DOI Google Scholar
[8]

Correa, D.; Scheuber, M. I.; Shan, H. M.; Weinmann, O. W.; Baumgartner, Y. A.; Harten, A.; Wahl, A. S.; Skaar, K. L.; Schwab, M. E. Intranasal delivery of full-length anti-nogo-A antibody: A potential alternative route for therapeutic antibodies to central nervous system targets. Proc. Natl. Acad. Sci. USA 2023, 120, e2200057120.
DOI Google Scholar
[9]

Terstappen, G. C.; Meyer, A. H.; Bell, R. D.; Zhang, W. D. Strategies for delivering therapeutics across the blood-brain barrier. Nat. Rev. Drug Discov. 2021, 20, 362–383.
DOI Google Scholar
[10]

Padmakumar, S.; Jones, G.; Pawar, G.; Khorkova, O.; Hsiao, J.; Kim, J.; Amiji, M. M.; Bleier, B. S. Minimally invasive nasal depot (MIND) technique for direct BDNF AntagoNAT delivery to the brain. J. Control. Release 2021, 331, 176–186.
DOI Google Scholar
[11]

Kou, D. D.; Gao, Y.; Li, C.; Zhou, D. D.; Lu, K.; Wang, N.; Zhang, R. R.; Yang, Z.; Zhou, Y.; Chen, L. et al. Intranasal pathway for nanoparticles to enter the central nervous system. Nano Lett. 2023, 23, 5381–5390.
DOI Google Scholar
[12]

Chen, W. L.; Yao, S.; Wan, J.; Tian, Y.; Huang, L.; Wang, S. S.; Akter, F.; Wu, Y. Q.; Yao, Y. Z.; Zhang, X. C. BBB-crossing adeno-associated virus vector:An excellent gene delivery tool for CNS disease treatment. J. Control. Release 2021, 333, 129–138.
DOI Google Scholar
[13]

Agrawal, M.; Saraf, S.; Saraf, S.; Antimisiaris, S. G.; Chougule, M. B.; Shoyele, S. A.; Alexander, A. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J. Control. Release 2018, 281, 139–177.
DOI Google Scholar
[14]

Meirinho, S.; Rodrigues, M.; Santos, A. O.; Falcão, A.; Alves, G. Self-emulsifying drug delivery systems: An alternative approach to improve brain bioavailability of poorly water-soluble drugs through intranasal administration. Pharmaceutics 2022, 14, 1487.
DOI Google Scholar
[15]

Kozlovskaya, L.; Abou-Kaoud, M.; Stepensky, D. Quantitative analysis of drug delivery to the brain via nasal route. J. Control. Release 2014, 189, 133–140.
DOI Google Scholar
[16]

Xie, J. B.; Shen, Z. Y.; Anraku, Y.; Kataoka, K.; Chen, X. Y. Nanomaterial-based blood-brain-barrier (BBB) crossing strategies. Biomaterials 2019, 224, 119491.
DOI Google Scholar
[17]

Ruigrok, M. J. R.; De Lange, E. C. M. Emerging insights for translational pharmacokinetic and pharmacokinetic-pharmacodynamic studies: Towards prediction of nose-to-brain transport in humans. Aaps. J. 2015, 17, 493–505.
DOI Google Scholar
[18]

Costa, C. P.; Moreira, J. N.; Lobo, J. M. S.; Silva, A. C. Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of in vivo studies. Acta Pharm. Sin. B 2021, 11, 925–940.
DOI Google Scholar
[19]

Battaglia, L.; Panciani, P. P.; Muntoni, E.; Capucchio, M. T.; Biasibetti, E.; De Bonis, P.; Mioletti, S.; Fontanella, M.; Swaminathan, S. Lipid nanoparticles for intranasal administration: Application to nose-to-brain delivery. Expert Opin. Drug Deliv. 2018, 15, 369–378.
DOI Google Scholar
[20]

Pires, P. C.; Santos, A. O. Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies. J. Control. Release 2018, 270, 89–100.
DOI Google Scholar
[21]

Kumar, N. N.; Lochhead, J. J.; Pizzo, M. E.; Nehra, G.; Boroumand, S.; Greene, G.; Thorne, R. G. Delivery of immunoglobulin G antibodies to the rat nervous system following intranasal administration: Distribution, dose-response, and mechanisms of delivery. J. Control. Release 2018, 286, 467–484.
DOI Google Scholar
[22]

Lee, M. R.; Shnitko, T. A.; Blue, S. W.; Kaucher, A. V.; Winchell, A. J.; Erikson, D. W.; Grant, K. A.; Leggio, L. Labeled oxytocin administered via the intranasal route reaches the brain in rhesus macaques. Nat. Commun. 2020, 11, 2783.
DOI Google Scholar
[23]

Veronesi, M. C.; Graner, B. D.; Cheng, S. H.; Zamora, M.; Zarrinmayeh, H.; Chen, C. T.; Das, S. K.; Vannier, M. W. Aerosolized in vivo 3D localization of nose-to-brain nanocarrier delivery using multimodality neuroimaging in a rat model-protocol development. Pharmaceutics 2021, 13, 391.
DOI Google Scholar
[24]

Van De Bittner, G. C.; Van De Bittner, K. C.; Wey, H. Y.; Rowe, W.; Dharanipragada, R.; Ying, X. Y.; Hurst, W.; Giovanni, A.; Alving, K.; Gupta, A. et al. Positron emission tomography assessment of the intranasal delivery route for orexin a. ACS Chem. Neurosci. 2018, 9, 358–368.
DOI Google Scholar
[25]

Wang, K.; Kumar, U. S.; Sadeghipour, N.; Massoud, T. F.; Paulmurugan, R. A microfluidics-based scalable approach to generate extracellular vesicles with enhanced therapeutic microrna loading for intranasal delivery to mouse glioblastomas. ACS Nano 2021, 15, 18327–18346.
DOI Google Scholar
[26]

Grassin-Delyle, S.; Buenestado, A.; Naline, E.; Faisy, C.; Blouquit-Laye, S.; Couderc, L. J.; Le Guen, M.; Fischler, M.; Devillier, P. Intranasal drug delivery: An efficient and non-invasive route for systemic administration: Focus on opioids. Pharmacol. Ther. 2012, 134, 366–379.
DOI Google Scholar
[27]

Torrens, A.; Ruiz, C. M.; Martinez, M. X.; Tagne, A. M.; Roy, P.; Grimes, D.; Ahmed, F.; Lallai, V.; Inshishian, V.; Bautista, M. et al. Nasal accumulation and metabolism of Δ9-tetrahydrocannabinol following aerosol (“vaping”) administration in an adolescent rat model. Pharmacol. Res. 2023, 187, 106600.
DOI Google Scholar
[28]

Chatterjee, B.; Gorain, B.; Mohananaidu, K.; Sengupta, P.; Mandal, U. K.; Choudhury, H. Targeted drug delivery to the brain via intranasal nanoemulsion: Available proof of concept and existing challenges. Int. J. Pharm. 2019, 565, 258–268.
DOI Google Scholar
[29]

Hemmat, A.; Ghassami, E.; Minaiyan, M.; Varshosaz, J. Magnetophoretic intranasal drug-loaded magnetic nano-aggregates as a platform for drug delivery in status epilepticus. Pharm. Nanotechnol. 2023, 11, 155–166.
DOI Google Scholar
[30]

Shringarpure, M.; Gharat, S.; Momin, M.; Omri, A. Management of epileptic disorders using nanotechnology-based strategies for nose-to-brain drug delivery. Exp. Opin. Drug Deliv. 2021, 18, 169–185.
DOI Google Scholar
[31]

Djupesland, P. G.; Messina, J. C.; Mahmoud, R. A. The nasal approach to delivering treatment for brain diseases: An anatomic, physiologic, and delivery technology overview. Ther. Deliv. 2014, 5, 709–733.
DOI Google Scholar
[32]

Pardeshi, C. V.; Belgamwar, V. S. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: An excellent platform for brain targeting. Exp. Opin. Drug Deliv. 2013, 10, 957–972.
DOI Google Scholar
[33]

Gänger, S.; Schindowski, K. Tailoring formulations for intranasal nose-to-brain delivery: A review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa. Pharmaceutics 2018, 10, 116.
DOI Google Scholar
[34]

Ogawa, K.; Uchida, M.; Yamaki, T.; Matsuzaki, H.; Kimura, M.; Okazaki, M.; Uchida, H.; Natsume, H. Delivery of acetaminophen to the central nervous system and the pharmacological effect after intranasal administration with a mucoadhesive agent and absorption enhancer. Int. J. Pharm. 2021, 594, 120046.
DOI Google Scholar
[35]

Jiang, Y. J.; Li, Y.; Liu, X. F. Intranasal delivery: Circumventing the iron curtain to treat neurological disorders. Exp. Opin. Drug Deliv. 2015, 12, 1717–1725.
DOI Google Scholar
[36]

Priester, M. I.; Ten Hagen, T. L. M. Image-guided drug delivery in nanosystem-based cancer therapies. Adv. Drug Deliv. Rev. 2023, 192, 114621.
DOI Google Scholar
[37]

Large, D. E.; Abdelmessih, R. G.; Fink, E. A.; Auguste, D. T. Liposome composition in drug delivery design, synthesis, characterization, and clinical application. Adv. Drug Deliv. Rev. 2021, 176, 113851.
DOI Google Scholar
[38]

Filipczak, N.; Pan, J. Y.; Yalamarty, S. S. K.; Torchilin, V. P. Recent advancements in liposome technology. Adv. Drug Deliv. Rev. 2020, 156, 4–22.
DOI Google Scholar
[39]

Almeida, B.; Nag, O. K.; Rogers, K. E.; Delehanty, J. B. Recent progress in bioconjugation strategies for liposome-mediated drug delivery. Molecules 2020, 25, 5672.
DOI Google Scholar
[40]

Allen, T. M.; Cullis, P. R. Liposomal drug delivery systems: From concept to clinical applications. Adv. Drug Deliv. Rev. 2013, 65, 36–48.
DOI Google Scholar
[41]

Singh, Y.; Meher, J. G.; Raval, K.; Khan, F. A.; Chaurasia, M.; Jain, N. K.; Chourasia, M. K. Nanoemulsion: Concepts, development and applications in drug delivery. J. Control. Release 2017, 252, 28–49.
DOI Google Scholar
[42]

Bozzato, E.; Bastiancich, C.; Préat, V. Nanomedicine: A useful tool against glioma stem cells. Cancers (Basel) 2020, 13, 9.
DOI Google Scholar
[43]

Saka, R.; Chella, N.; Khan, W. Development of imatinib mesylate-loaded liposomes for nose to brain delivery: In vitro and in vivo evaluation. Aaps PharmSciTech 2021, 22, 192.
DOI Google Scholar
[44]

Rideau, E.; Dimova, R.; Schwille, P.; Wurm, F. R.; Landfester, K. Liposomes and polymersomes: A comparative review towards cell mimicking. Chem. Soc. Rev. 2018, 47, 8572–8610.
DOI Google Scholar
[45]

Machut-Binkowski, C.; Hapiot, F.; Cecchelli, R.; Martin, P.; Monflier, E. A versatile liposome/cyclodextrin supramolecular carrier for drug delivery through the blood-brain barrier. J. Incl. Phenom. Macrocycl. Chem. 2007, 57, 567–572.
DOI Google Scholar
[46]

Kurano, T.; Kanazawa, T.; Ooba, A.; Masuyama, Y.; Maruhana, N.; Yamada, M.; Iioka, S.; Ibaraki, H.; Kosuge, Y.; Kondo, H. et al. Nose-to-brain/spinal cord delivery kinetics of liposomes with different surface properties. J. Control. Release 2022, 344, 225–234.
DOI Google Scholar
[47]

Pashirova, T. N.; Zueva, I. V.; Petrov, K. A.; Lukashenko, S. S.; Nizameev, I. R.; Kulik, N. V.; Voloshina, A. D.; Almasy, L.; Kadirov, M. K.; Masson, P. et al. Mixed cationic liposomes for brain delivery of drugs by the intranasal route: The acetylcholinesterase reactivator 2-PAM as encapsulated drug model. Colloids Surf. Biointerf. 2018, 171, 358–367.
DOI Google Scholar
[48]

Dhaval, M.; Vaghela, P.; Patel, K.; Sojitra, K.; Patel, M.; Patel, S.; Dudhat, K.; Shah, S.; Manek, R.; Parmar, R. Lipid-based emulsion drug delivery systems—A comprehensive review. Drug Deliv. Transl. Res. 2022, 12, 1616–1639.
DOI Google Scholar
[49]

Dhaliwal, H. K.; Fan, Y. F.; Kim, J.; Amiji, M. M. Intranasal delivery and transfection of mRNA therapeutics in the brain using cationic liposomes. Mol. Pharmaceutics 2020, 17, 1996–2005.
DOI Google Scholar
[50]

Jojo, G. M.; Kuppusamy, G.; De, A.; Karri, V. V. S. N. R. Formulation and optimization of intranasal nanolipid carriers of pioglitazone for the repurposing in Alzheimer’s disease using Box-Behnken design. Drug Dev. Ind. Pharm. 2019, 45, 1061–1072.
DOI Google Scholar
[51]

Guo, X. L.; Zheng, H.; Guo, Y. T.; Wang, Y.; Anderson, G. J.; Ci, Y.; Yu, P.; Geng, L. N.; Chang, Y. Z. Nasal delivery of nanoliposome-encapsulated ferric ammonium citrate can increase the iron content of rat brain. J. Nanobiotechnol. 2017, 15, 42.
DOI Google Scholar
[52]

Azambuja, J. H.; Schuh, R. S.; Michels, L. R.; Gelsleichter, N. E.; Beckenkamp, L. R.; Iser, I. C.; Lenz, G. S.; De Oliveira, F. H.; Venturin, G.; Greggio, S. et al. Nasal administration of cationic nanoemulsions as CD73-siRNA delivery system for glioblastoma treatment: A new therapeutical approach. Mol. Neurobiol. 2020, 57, 635–649.
DOI Google Scholar
[53]

Kaur, A.; Nigam, K.; Srivastava, S.; Tyagi, A.; Dang, S. Memantine nanoemulsion: A new approach to treat Alzheimer’s disease. J. Microencapsul. 2020, 37, 355–365.
DOI Google Scholar
[54]

Fachel, F. N. S.; Medeiros-Neves, B.; Dal Prá, M.; Schuh, R. S.; Veras, K. S.; Bassani, V. L.; Koester, L. S.; Henriques, A. T.; Braganhol, E.; Teixeira, H. F. Box-Behnken design optimization of mucoadhesive chitosan-coated nanoemulsions for rosmarinic acid nasal delivery—In vitro studies. Carbohydr. Polym. 2018, 199, 572–582.
DOI Google Scholar
[55]

Sarheed, O.; Shouqair, D.; Ramesh, K. V. R. N. S.; Khaleel, T.; Amin, M.; Boateng, J.; Drechsler, M. Formation of stable nanoemulsions by ultrasound-assisted two-step emulsification process for topical drug delivery: Effect of oil phase composition and surfactant concentration and loratadine as ripening inhibitor. Int. J. Pharm. 2020, 576, 118952.
DOI Google Scholar
[56]

Kanazawa, T.; Akiyama, F.; Kakizaki, S.; Takashima, Y.; Seta, Y. Delivery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating peptide-modified nano-micelles. Biomaterials 2013, 34, 9220–9226.
DOI Google Scholar
[57]

Nour, S. A.; Abdelmalak, N. S.; Naguib, M. J.; Rashed, H. M.; Ibrahim, A. B. Intranasal brain-targeted clonazepam polymeric micelles for immediate control of status epilepticus: In vitro optimization, ex vivo determination of cytotoxicity, in vivo biodistribution and pharmacodynamics studies. Drug Deliv. 2016, 23, 3681–3695.
DOI Google Scholar
[58]

Liu, S. S.; Yang, S. L.; Ho, P. C. Intranasal administration of carbamazepine-loaded carboxymethyl chitosan nanoparticles for drug delivery to the brain. Asian J. Pharm. Sci. 2018, 13, 72–81.
DOI Google Scholar
[59]

Ahmed, T. A.; El-Say, K. M.; Ahmed, O. A. A.; Aljaeid, B. M. Superiority of TPGS-loaded micelles in the brain delivery of vinpocetine via administration of thermosensitive intranasal gel. Int. J. Nanomed. 2019, 14, 5555–5567.
DOI Google Scholar
[60]

Zhang, L.; Yang, S. L.; Wong, L. R.; Xie, H.; Ho, P. C. L. In vitro and in vivo comparison of curcumin-encapsulated chitosan-coated poly(lactic-co-glycolic acid) nanoparticles and curcumin/hydroxypropyl-β-cyclodextrin inclusion complexes administered intranasally as therapeutic strategies for Alzheimer’s disease. Mol. Pharmaceutics 2020, 17, 4256–4269.
DOI Google Scholar
[61]

Zameer, S.; Ali, J.; Vohora, D.; Najmi, A. K.; Akhtar, M. Development, optimisation and evaluation of chitosan nanoparticles of alendronate against Alzheimer’s disease in intracerebroventricular streptozotocin model for brain delivery. J. Drug Target. 2021, 29, 199–216.
DOI Google Scholar
[62]

Burilova, E. A.; Pashirova, T. N.; Zueva, I. V.; Gibadullina, E. M.; Lushchekina, S. V.; Sapunova, A. S.; Kayumova, R. M.; Rogov, A. M.; Evtjugin, V. G.; Sudakov, I. A. et al. Bi-functional sterically hindered phenol lipid-based delivery systems as potential multi-target agents against Alzheimer’s disease via an intranasal route. Nanoscale 2020, 12, 13757–13770.
DOI Google Scholar
[63]

Muntimadugu, E.; Dhommati, R.; Jain, A.; Challa, V. G. S.; Shaheen, M.; Khan, W. Intranasal delivery of nanoparticle encapsulated tarenflurbil: A potential brain targeting strategy for Alzheimer’s disease. Eur. J. Pharm. Sci. 2016, 92, 224–234.
DOI Google Scholar
[64]

Samaridou, E.; Walgrave, H.; Salta, E.; Álvarez, D. M.; Castro-López, V.; Loza, M.; Alonso, M. J. Nose-to-brain delivery of enveloped RNA-cell permeating peptide nanocomplexes for the treatment of neurodegenerative diseases. Biomaterials 2020, 230, 119657.
DOI Google Scholar
[65]

Yang, H.; Mu, W. H.; Wei, D. H.; Zhang, Y.; Duan, Y.; Gao, J. X.; Gong, X. Q.; Wang, H. J.; Wu, X. L.; Tao, H. et al. A novel targeted and high-efficiency nanosystem for combinational therapy for Alzheimer’s disease. Adv. Sci. (Weinh.) 2020, 7, 1902906.
DOI Google Scholar
[66]

Sukumar, U. K.; Bose, R. J. C.; Malhotra, M.; Babikir, H. A.; Afjei, R.; Robinson, E.; Zeng, Y. T.; Chang, E.; Habte, F.; Sinclair, R. et al. Intranasal delivery of targeted polyfunctional gold-iron oxide nanoparticles loaded with therapeutic microRNAs for combined theranostic multimodality imaging and presensitization of glioblastoma to temozolomide. Biomaterials 2019, 218, 119342.
DOI Google Scholar
[67]

Sousa, F.; Dhaliwal, H. K.; Gattacceca, F.; Sarmento, B.; Amiji, M. M. Enhanced anti-angiogenic effects of bevacizumab in glioblastoma treatment upon intranasal administration in polymeric nanoparticles. J. Control. Release 2019, 309, 37–47.
DOI Google Scholar
[68]

Shah, B. Microemulsion as a promising carrier for nose to brain delivery: Journey since last decade. J. Pharm. Investig. 2021, 51, 611–634.
DOI Google Scholar
[69]

Iqbal, R.; Ahmed, S.; Jain, G. K.; Vohora, D. Design and development of letrozole nanoemulsion: A comparative evaluation of brain targeted nanoemulsion with free letrozole against status epilepticus and neurodegeneration in mice. Int. J. Pharm. 2019, 565, 20–32.
DOI Google Scholar
[70]

Wik, J.; Bansal, K. K.; Assmuth, T.; Rosling, A.; Rosenholm, J. M. Facile methodology of nanoemulsion preparation using oily polymer for the delivery of poorly soluble drugs. Drug Deliv. Transl. Res. 2020, 10, 1228–1240.
DOI Google Scholar
[71]

Roy, A.; Nishchaya, K.; Rai, V. K. Nanoemulsion-based dosage forms for the transdermal drug delivery applications: A review of recent advances. Expert Opin. Drug Deliv. 2022, 19, 303–319.
DOI Google Scholar
[72]

Handa, M.; Tiwari, S.; Yadav, A. K.; Almalki, W. H.; Alghamdi, S.; Alharbi, K. S.; Shukla, R.; Beg, S. Therapeutic potential of nanoemulsions as feasible wagons for targeting Alzheimer’s disease. Drug Discov. Today 2021, 26, 2881–2888.
DOI Google Scholar
[73]

Ozogul, Y.; Karsli, G. T.; Durmuş, M.; Yazgan, H.; Oztop, H. M.; McClements, D. J.; Ozogul, F. Recent developments in industrial applications of nanoemulsions. Adv. Colloid Interface Sci. 2022, 304, 102685.
DOI Google Scholar
[74]

Richa, R.; Roy Choudhury, A. Exploration of polysaccharide based nanoemulsions for stabilization and entrapment of curcumin. Int. J. Biol. Macromol. 2020, 156, 1287–1296.
DOI Google Scholar
[75]

Cheng, L. C.; Hashemnejad, S. M.; Zarket, B.; Muthukrishnan, S.; Doyle, P. S. Thermally and pH-responsive gelation of nanoemulsions stabilized by weak acid surfactants. J. Colloid Interface Sci. 2020, 563, 229–240.
DOI Google Scholar
[76]

Carpenter, J.; Saharan, V. K. Ultrasonic assisted formation and stability of mustard oil in water nanoemulsion: Effect of process parameters and their optimization. Ultrason. Sonochem. 2017, 35, 422–430.
DOI Google Scholar
[77]

Manickam, S.; Sivakumar, K.; Pang, C. H. Investigations on the generation of oil-in-water (O/W) nanoemulsions through the combination of ultrasound and microchannel. Ultrason. Sonochem. 2020, 69, 105258.
DOI Google Scholar
[78]

Bader, H.; Ringsdorf, H.; Schmidt, B. Watersoluble polymers in medicine. Die Angew. Makromol. Chem. 1984, 123, 457–485.
DOI Google Scholar
[79]

Hari, S. K.; Gauba, A.; Shrivastava, N.; Tripathi, R. M.; Jain, S. K.; Pandey, A. K. Polymeric micelles and cancer therapy: An ingenious multimodal tumor-targeted drug delivery system. Drug Deliv. Transl. Res. 2023, 13, 135–163.
DOI Google Scholar
[80]

Van Strien, J.; Escalona-Rayo, O.; Jiskoot, W.; Slütter, B.; Kros, A. Elastin-like polypeptide-based micelles as a promising platform in nanomedicine. J. Control. Release 2023, 353, 713–726.
DOI Google Scholar
[81]

Pokharkar, V.; Suryawanshi, S.; Dhapte-Pawar, V. Exploring micellar-based polymeric systems for effective nose-to-brain drug delivery as potential neurotherapeutics. Drug Deliv. Transl. Res. 2020, 10, 1019–1031.
DOI Google Scholar
[82]

Lu, Y.; Zhang, E. S.; Yang, J. H.; Cao, Z. Q. Strategies to improve micelle stability for drug delivery. Nano Res. 2018, 11, 4985–4998.
DOI Google Scholar
[83]

Zhou, Q. Y.; Zhao, T. C.; Liu, M. L.; Yin, D. R.; Liu, M. C.; Elzatahry, A. A.; Zhang, F.; Zhao, D. Y.; Li, X. M. Highly stable hybrid single-micelle: A universal nanocarrier for hydrophobic bioimaging agents. Nano Res. 2022, 15, 4582–4589.
DOI Google Scholar
[84]

Kamegawa, R.; Naito, M.; Miyata, K. Functionalization of silica nanoparticles for nucleic acid delivery. Nano Res. 2018, 11, 5219–5239.
DOI Google Scholar
[85]

Yu, C. C.; Li, K.; Xu, L.; Li, B.; Li, C. H.; Guo, S.; Li, Z. Y.; Zhang, Y. Q.; Hussain, A.; Tan, H. et al. siRNA-functionalized lanthanide nanoparticle enables efficient endosomal escape and cancer treatment. Nano Res. 2022, 15, 9160–9168.
DOI Google Scholar
[86]

Yi, X. Q.; Zeng, W. J.; Wang, C.; Chen, Y.; Zheng, L. Y.; Zhu, X. L.; Ke, Y. Q.; He, X. Y.; Kuang, Y.; Huang, Q. T. A step-by-step multiple stimuli-responsive metal-phenolic network prodrug nanoparticles for chemotherapy. Nano Res. 2022, 15, 1205–1212.
DOI Google Scholar
[87]

Jeong, S. H.; Jang, J. H.; Cho, H. Y.; Lee, Y. B. Soft- and hard-lipid nanoparticles: A novel approach to lymphatic drug delivery. Arch. Pharm. Res. 2018, 41, 797–814.
DOI Google Scholar
[88]

Anderluzzi, G.; Lou, G.; Su, Y.; Perrie, Y. Scalable manufacturing processes for solid lipid nanoparticles. Pharm. Nanotechnol. 2019, 7, 444–459.
DOI Google Scholar
[89]

Nasirizadeh, S.; Malaekeh-Nikouei, B. Solid lipid nanoparticles and nanostructured lipid carriers in oral cancer drug delivery. J. Drug Deliv. Sci. Technol. 2020, 55, 101458.
DOI Google Scholar
[90]

De Oliveira Junior, E. R.; Truzzi, E.; Ferraro, L.; Fogagnolo, M.; Pavan, B.; Beggiato, S.; Rustichelli, C.; Maretti, E.; Lima, E. M.; Leo, E. et al. Nasal administration of nanoencapsulated geraniol/ursodeoxycholic acid conjugate: Towards a new approach for the management of Parkinson’s disease. J. Control. Release 2020, 321, 540–552.
DOI Google Scholar
[91]

Hasan, N.; Imran, M.; Kesharwani, P.; Khanna, K.; Karwasra, R.; Sharma, N.; Rawat, S.; Sharma, D.; Ahmad, F. J.; Jain, G. K. et al. Intranasal delivery of naloxone-loaded solid lipid nanoparticles as a promising simple and non-invasive approach for the management of opioid overdose. Int. J. Pharm. 2021, 599, 120428.
DOI Google Scholar
[92]

Uppuluri, C. T.; Ravi, P. R.; Dalvi, A. V. Design, optimization and pharmacokinetic evaluation of piribedil loaded solid lipid nanoparticles dispersed in nasal in situ gelling system for effective management of Parkinson’s disease. Int. J. Pharm. 2021, 606, 120881.
DOI Google Scholar
[93]

Akel, H.; Ismail, R.; Csóka, I. Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in Alzheimer’s disease. Eur. J. Pharm. Biopharm. 2020, 148, 38–53.
DOI Google Scholar
[94]

Correia, A. C.; Monteiro, A. R.; Silva, R.; Moreira, J. N.; Lobo, J. M. S.; Silva, A. C. Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood-brain barrier (BBB) to manage neurological disorders. Adv. Drug Deliv. Rev. 2022, 189, 114485.
DOI Google Scholar
[95]

Costa, C.; Moreira, J. N.; Amaral, M. H.; Lobo, J. M. S.; Silva, A. C. Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis. J. Control. Release 2019, 295, 187–200.
DOI Google Scholar
[96]

Keck, C. M.; Specht, D.; Brüßler, J. Influence of lipid matrix composition on biopharmaceutical properties of lipid nanoparticles. J. Control. Release 2021, 338, 149–163.
DOI Google Scholar
[97]

Kovačević, A. B.; Müller, R. H.; Keck, C. M. Formulation development of lipid nanoparticles: Improved lipid screening and development of tacrolimus loaded nanostructured lipid carriers (NLC). Int. J. Pharm. 2020, 576, 118918.
DOI Google Scholar
[98]

Dana, P.; Yostawonkul, J.; Chonniyom, W.; Unger, O.; Sakulwech, S.; Sathornsumetee, S.; Saengkrit, N. Nanostructured lipid base carrier for specific delivery of garlic oil through blood brain barrier against aggressiveness of glioma. J. Drug Deliv. Sci. Technol. 2021, 64, 102651.
DOI Google Scholar
[99]

Agbo, C. P.; Ugwuanyi, T. C.; Ugwuoke, W. I.; McConville, C.; Attama, A. A.; Ofokansi, K. C. Intranasal artesunate-loaded nanostructured lipid carriers: A convenient alternative to parenteral formulations for the treatment of severe and cerebral malaria. J. Control. Release 2021, 334, 224–236.
DOI Google Scholar
[100]

Nguyen, T. T. L.; Maeng, H. J. Pharmacokinetics and pharmacodynamics of intranasal solid lipid nanoparticles and nanostructured lipid carriers for nose-to-brain delivery. Pharmaceutics 2022, 14, 572.
DOI Google Scholar
[101]

Hong, S. S.; Oh, K. T.; Choi, H. G.; Lim, S. J. Liposomal formulations for nose-to-brain delivery: Recent advances and future perspectives. Pharmaceutics 2019, 11, 540.
DOI Google Scholar
[102]

Ahmad, E.; Feng, Y. H.; Qi, J. P.; Fan, W. F.; Ma, Y. H.; He, H. S.; Xia, F.; Dong, X. C.; Zhao, W. L.; Lu, Y. et al. Evidence of nose-to-brain delivery of nanoemulsions: Cargoes but not vehicles. Nanoscale 2017, 9, 1174–1183.
DOI Google Scholar
[103]

Le, M. Q.; Carpentier, R.; Lantier, I.; Ducournau, C.; Dimier-Poisson, I.; Betbeder, D. Residence time and uptake of porous and cationic maltodextrin-based nanoparticles in the nasal mucosa: Comparison with anionic and cationic nanoparticles. Int. J. Pharm. 2018, 550, 316–324.
DOI Google Scholar
[104]

Guo, T. W.; Guo, Y. Y.; Gong, Y. H.; Ji, J. G.; Hao, S. L.; Deng, J.; Wang, B. C. An enhanced charge-driven intranasal delivery of nicardipine attenuates brain injury after intracerebral hemorrhage. Int. J. Pharm. 2019, 566, 46–56.
DOI Google Scholar
[105]

Suk, J. S.; Xu, Q. G.; Kim, N.; Hanes, J.; Ensign, L. M. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 2016, 99, 28–51.
DOI Google Scholar
[106]

Chaudhury, S. S.; Nandi, M.; Kumar, K.; Ruidas, B.; Sur, T. K.; Prasad, P.; Chakrabarti, S.; De, P.; Sil, J.; Das Mukhopadhyay, C. Rodent model preclinical assessment of PEGylated block copolymer targeting cognition and oxidative stress insults of Alzheimer’s disease. Mol. Neurobiol. 2023, 60, 2036–2050.
DOI Google Scholar
[107]

Goel, H.; Kalra, V.; Verma, S. K.; Dubey, S. K.; Tiwary, A. K. Convolutions in the rendition of nose to brain therapeutics from bench to bedside: Feats & fallacies. J. Control. Release 2022, 341, 782–811.
DOI Google Scholar
[108]

Schlachet, I.; Sosnik, A. Mixed mucoadhesive amphiphilic polymeric nanoparticles cross a model of nasal septum epithelium in vitro. ACS Appl. Mater. Interfaces 2019, 11, 21360–21371.
DOI Google Scholar
[109]

Guimaraes, M. E. N.; Lopez-Blanco, R.; Correa, J.; Fernandez-Villamarin, M.; Bistué, M. B.; Martino-Adami, P.; Morelli, L.; Kumar, V.; Wempe, M. F.; Cuello, A. C. et al. Liver X receptor activation with an intranasal polymer therapeutic prevents cognitive decline without altering lipid levels. ACS Nano 2021, 15, 4678–4687.
DOI Google Scholar
[110]

Law, L. H.; Huang, J. P.; Xiao, P.; Liu, Y.; Chen, Z. L.; Lai, J. H. C.; Han, X. Q.; Cheng, G. W. Y.; Tse, K. H.; Chan, K. W. Y. Multiple CEST contrast imaging of nose-to-brain drug delivery using Iohexol liposomes at 3T MRI. J. Control. Release 2023, 354, 208–220.
DOI Google Scholar
[111]

Teo, S. L. Y.; Rennick, J. J.; Yuen, D.; Al-Wassiti, H.; Johnston, A. P. R.; Pouton, C. W. Unravelling cytosolic delivery of cell penetrating peptides with a quantitative endosomal escape assay. Nat. Commun. 2021, 12, 3721.
DOI Google Scholar
[112]

Zorko, M.; Jones, S.; Langel, Ü. Cell-penetrating peptides in protein mimicry and cancer therapeutics. Adv. Drug Deliv. Rev. 2022, 180, 114044.
DOI Google Scholar
[113]

Tian, Y.; Zhou, S. B. Advances in cell penetrating peptides and their functionalization of polymeric nanoplatforms for drug delivery. WIREs Nanomed. Nanobiotechnol. 2021, 13, e1668.
DOI Google Scholar
[114]

Xu, J. K.; Khan, A. R.; Fu, M. F.; Wang, R. J.; Ji, J. B.; Zhai, G. X. Cell-penetrating peptide: A means of breaking through the physiological barriers of different tissues and organs. J. Control. Release 2019, 309, 106–124.
DOI Google Scholar
[115]

Yoo, D. Y.; Barros, S. A.; Brown, G. C.; Rabot, C.; Bar-Sagi, D.; Arora, P. S. Macropinocytosis as a key determinant of peptidomimetic uptake in cancer cells. J. Am. Chem. Soc. 2020, 142, 14461–14471.
DOI Google Scholar
[116]

Patel, S. G.; Sayers, E. J.; He, L.; Narayan, R.; Williams, T. L.; Mills, E. M.; Allemann, R. K.; Luk, L. Y. P.; Jones, A. T.; Tsai, Y. H. Cell-penetrating peptide sequence and modification dependent uptake and subcellular distribution of green florescent protein in different cell lines. Sci. Rep. 2019, 9, 6298.
DOI Google Scholar
[117]

Liu, Y. K.; Zhao, Z. H.; Li, M. Overcoming the cellular barriers and beyond: Recent progress on cell penetrating peptide modified nanomedicine in combating physiological and pathological barriers. Asian J. Pharm. Sci. 2022, 17, 523–543.
DOI Google Scholar
[118]

Akita, T.; Oda, Y.; Kimura, R.; Nagai, M.; Tezuka, A.; Shimamura, M.; Washizu, K.; Oka, J. I.; Yamashita, C. Involvement of trigeminal axons in nose-to-brain delivery of glucagon-like peptide-2 derivative. J. Control. Release 2022, 351, 573–580.
DOI Google Scholar
[119]

Akita, T.; Kimura, R.; Akaguma, S.; Nagai, M.; Nakao, Y.; Tsugane, M.; Suzuki, H.; Oka, J. I.; Yamashita, C. Usefulness of cell-penetrating peptides and penetration accelerating sequence for nose-to-brain delivery of glucagon-like peptide-2. J. Control. Release 2021, 335, 575–583.
DOI Google Scholar
[120]

Lin, T. T.; Liu, E. G.; He, H. N.; Shin, M. C.; Moon, C.; Yang, V. C.; Huang, Y. Z. Nose-to-brain delivery of macromolecules mediated by cell-penetrating peptides. Acta Pharm. Sin. B 2016, 6, 352–358.
DOI Google Scholar
[121]

Hou, Q. H.; Wang, L. L.; Xiao, F.; Wang, L.; Liu, X. Y.; Zhu, L. N.; Lu, Y.; Zheng, W. F.; Jiang, X. Y. Dual targeting nanoparticles for epilepsy therapy. Chem. Sci. 2022, 13, 12913–12920.
DOI Google Scholar
[122]

Copolovici, D. M.; Langel, K.; Eriste, E.; Langel, Ü. Cell-penetrating peptides: Design, synthesis, and applications. ACS Nano 2014, 8, 1972–1994.
DOI Google Scholar
[123]

Chen, K. Y.; Pei, D. H. Engineering cell-permeable proteins through insertion of cell-penetrating motifs into surface loops. ACS Chem. Biol. 2020, 15, 2568–2576.
DOI Google Scholar
[124]

Kanazawa, T.; Taki, H.; Okada, H. Nose-to-brain drug delivery system with ligand/cell-penetrating peptide-modified polymeric nano-micelles for intracerebral gliomas. Eur. J. Pharm. Biopharm. 2020, 152, 85–94.
DOI Google Scholar
[125]

Van Niel, G.; D’Angelo, G.; Raposo, G. Shedding light on the cell biology of extracellular vesicles. Nat. Rev. Mol. Cell Biol. 2018, 19, 213–228.
DOI Google Scholar
[126]

Wu, J.; Ma, L.; Sun, D. N.; Zhang, X. R.; Cui, J. W.; Du, Y. J.; Guo, Y. M.; Wang, X.; Di, L. Q.; Wang, R. N. Bioengineering extracellular vesicles as novel nanocarriers towards brain disorders. Nano Res. 2023, 16, 2635–2659.
DOI Google Scholar
[127]

Maeki, M.; Kimura, N.; Sato, Y.; Harashima, H.; Tokeshi, M. Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems. Adv. Drug Deliv. Rev. 2018, 128, 84–100.
DOI Google Scholar
[128]

Ke, W. N.; Afonin, K. A. Exosomes as natural delivery carriers for programmable therapeutic nucleic acid nanoparticles (NANPs). Adv. Drug Deliv. Rev. 2021, 176, 113835.
DOI Google Scholar
[129]

Jiang, X. C.; Zhang, T. Y.; Gao, J. Q. The in vivo fate and targeting engineering of crossover vesicle-based gene delivery system. Adv. Drug Deliv. Rev. 2022, 187, 114324.
DOI Google Scholar
[130]

Li, Y. S.; Wu, H. H.; Jiang, X. C.; Dong, Y. F.; Zheng, J. J.; Gao, J. Q. New idea to promote the clinical applications of stem cells or their extracellular vesicles in central nervous system disorders: Combining with intranasal delivery. Acta Pharm. Sin. B 2022, 12, 3215–3232.
DOI Google Scholar
[131]

Herman, S.; Fishel, I.; Offen, D. Intranasal delivery of mesenchymal stem cells-derived extracellular vesicles for the treatment of neurological diseases. Stem Cells 2021, 39, 1589–1600.
DOI Google Scholar
[132]

Liu, B.; Kong, Y. F.; Shi, W.; Kuss, M.; Liao, K.; Hu, G. K.; Xiao, P.; Sankarasubramanian, J.; Guda, C.; Wang, X. L. et al. Exosomes derived from differentiated human ADMSC with the Schwann cell phenotype modulate peripheral nerve-related cellular functions. Bioact. Mater. 2022, 14, 61–75.
DOI Google Scholar
[133]

Labusek, N.; Mouloud, Y.; Köster, C.; Diesterbeck, E.; Tertel, T.; Wiek, C.; Hanenberg, H.; Horn, P. A.; Felderhoff-Müser, U.; Bendix, I. et al. Extracellular vesicles from immortalized mesenchymal stromal cells protect against neonatal hypoxic-ischemic brain injury. Inflamm. Regen. 2023, 43, 24.
DOI Google Scholar
[134]

Peng, H.; Li, Y.; Ji, W. H.; Zhao, R. C.; Lu, Z. G.; Shen, J.; Wu, Y. Y.; Wang, J. Z.; Hao, Q. L.; Wang, J. W. et al. Intranasal administration of self-oriented nanocarriers based on therapeutic exosomes for synergistic treatment of Parkinson’s disease. ACS Nano 2022, 16, 869–884.
DOI Google Scholar
[135]

Raguraman, R.; Bhavsar, D.; Kim, D.; Ren, X. Y.; Sikavitsas, V.; Munshi, A.; Ramesh, R. Tumor-targeted exosomes for delivery of anticancer drugs. Cancer Lett. 2023, 558, 216093.
DOI Google Scholar
[136]

Dasgupta, A.; Sun, T.; Palomba, R.; Rama, E.; Zhang, Y. Z.; Power, C.; Moeckel, D.; Liu, M. J.; Sarode, A.; Weiler, M. et al. Nonspherical ultrasound microbubbles. Proc. Natl. Acad. Sci. USA 2023, 120, e2218847120.
DOI Google Scholar
[137]

Gorick, C. M.; Breza, V. R.; Nowak, K. M.; Cheng, V. W. T.; Fisher, D. G.; Debski, A. C.; Hoch, M. R.; Demir, Z. E. F.; Tran, N. M.; Schwartz, M. R. et al. Applications of focused ultrasound-mediated blood-brain barrier opening. Adv. Drug Deliv. Rev. 2022, 191, 114583.
DOI Google Scholar
[138]

Ye, D. Z.; Luan, J. Y.; Pang, H.; Yang, Y. H.; Nazeri, A.; Rubin, J. B.; Chen, H. Characterization of focused ultrasound-mediated brainstem delivery of intranasally administered agents. J. Control. Release 2020, 328, 276–285.
DOI Google Scholar
[139]

Chen, H.; Chen, C. C.; Acosta, C.; Wu, S. Y.; Sun, T.; Konofagou, E. E. A new brain drug delivery strategy: Focused ultrasound-enhanced intranasal drug delivery. PLoS One 2014, 9, e108880.
DOI Google Scholar
[140]

Ye, D. Z.; Zhang, X. H.; Yue, Y. M.; Raliya, R.; Biswas, P.; Taylor, S.; Tai, Y. C.; Rubin, J. B.; Liu, Y. J.; Chen, H. Focused ultrasound combined with microbubble-mediated intranasal delivery of gold nanoclusters to the brain. J. Control. Release 2018, 286, 145–153.
DOI Google Scholar
[141]

Ye, D. Z.; Yuan, J. Y.; Yang, Y. H.; Yue, Y. M.; Hu, Z. T.; Fadera, S.; Chen, H. Incisionless targeted adeno-associated viral vector delivery to the brain by focused ultrasound-mediated intranasal administration. eBioMedicine 2022, 84, 104277.
DOI Google Scholar
[142]

Ye, D. Z.; Sultan, D.; Zhang, X. H.; Yue, Y. M.; Heo, G. S.; Kothapalli, S. V. V. N.; Luehmann, H.; Tai, Y. C.; Rubin, J. B.; Liu, Y. et al. Focused ultrasound-enabled delivery of radiolabeled nanoclusters to the pons. J. Control. Release 2018, 283, 143–150.
DOI Google Scholar
[143]

Dimatteo, R.; Darling, N. J.; Segura, T. In situ forming injectable hydrogels for drug delivery and wound repair. Adv. Drug Deliv. Rev. 2018, 127, 167–184.
DOI Google Scholar
[144]

Shah, S.; Rangaraj, N.; Laxmikeshav, K.; Sampathi, S. “Nanogels as drug carriers—Introduction, chemical aspects, release mechanisms and potential applications”. Int. J. Pharm. 2020, 581, 119268.
DOI Google Scholar
[145]

Ayoubi-Joshaghani, M. H.; Seidi, K.; Azizi, M.; Jaymand, M.; Javaheri, T.; Jahanban-Esfahlan, R.; Hamblin, M. R. Potential applications of advanced nano/hydrogels in biomedicine: Static, dynamic, multi-stage, and bioinspired. Adv. Funct. Mater. 2020, 30, 2004098.
DOI Google Scholar
[146]

Kandil, R.; Merkel, O. M. Recent progress of polymeric nanogels for gene delivery. Curr. Opin. Colloid Interface Sci. 2019, 39, 11–23.
DOI Google Scholar
[147]

Salatin, S.; Barar, J.; Barzegar-Jalali, M.; Adibkia, K.; Milani, M. A.; Jelvehgari, M. Hydrogel nanoparticles and nanocomposites for nasal drug/vaccine delivery. Arch. Pharm. Res. 2016, 39, 1181–1192.
DOI Google Scholar
[148]

Kim, Y. S.; Sung, D. K.; Kim, H.; Kong, W. H.; Kim, Y. E.; Hahn, S. K. Nose-to-brain delivery of hyaluronate—FG loop peptide conjugate for non-invasive hypoxic-ischemic encephalopathy therapy. J. Control. Release 2019, 307, 76–89.
DOI Google Scholar
[149]

Majcher, M. J.; Babar, A.; Lofts, A.; Leung, A.; Li, X. Y.; Abu-Hijleh, F.; Smeets, N. M. B.; Mishra, R. K.; Hoare, T. In situ-gelling starch nanoparticle (SNP)/O-carboxymethyl chitosan (CMCh) nanoparticle network hydrogels for the intranasal delivery of an antipsychotic peptide. J. Control. Release 2021, 330, 738–752.
DOI Google Scholar
[150]

Li, X. M.; Tsibouklis, J.; Weng, T. T.; Zhang, B. N.; Yin, G. Q.; Feng, G. Z.; Cui, Y. D.; Savina, I. N.; Mikhalovska, L. I.; Sandeman, S. R. et al. Nano carriers for drug transport across the blood-brain barrier. J. Drug Target. 2017, 25, 17–28.
DOI Google Scholar
[151]

Khatri, D. K.; Preeti, K.; Tonape, S.; Bhattacharjee, S.; Patel, M.; Shah, S.; Singh, P. K.; Srivastava, S.; Gugulothu, D.; Vora, L. et al. Nanotechnological advances for nose to brain delivery of therapeutics to improve the Parkinson therapy. Curr. Neuropharmacol. 2023, 21, 493–516.
DOI Google Scholar
[152]

Kumar, A.; Pandey, A. N.; Jain, S. K. Nasal-nanotechnology: Revolution for efficient therapeutics delivery. Drug Deliv. 2016, 23, 671–683.
DOI Google Scholar
[153]

Hu, Y.; Jiang, K.; Wang, D. L.; Yao, S. Y.; Lu, L. W.; Wang, H.; Song, J.; Zhou, J. F.; Fan, X. Y.; Wang, Y. et al. Core–shell lipoplexes inducing active macropinocytosis promote intranasal delivery of c-Myc siRNA for treatment of glioblastoma. Acta Biomater. 2022, 138, 478–490.
DOI Google Scholar
[154]

Tian, Y.; Zheng, Z. Y.; Wang, X.; Liu, S. Z.; Gu, L. W.; Mu, J.; Zheng, X. J.; Li, Y. J.; Shen, S. Establishment and evaluation of glucose-modified nanocomposite liposomes for the treatment of cerebral malaria. J. Nanobiotechnol. 2022, 20, 318.
DOI Google Scholar
[155]

Gadhave, D.; Tupe, S.; Tagalpallewar, A.; Gorain, B.; Choudhury, H.; Kokare, C. Nose-to-brain delivery of amisulpride-loaded lipid-based poloxamer-gellan gum nanoemulgel: In vitro and in vivo pharmacological studies. Int. J. Pharm. 2021, 607, 121050.
DOI Google Scholar
[156]
Shen, X.; Cui, Z. X.; Wei, Y. D.; Huo, Y. N.; Yu, D.; Zhang, X.; Mao, S. R. Exploring the potential to enhance drug distribution in the brain subregion via intranasal delivery of nanoemulsion in combination with borneol as a guider. Asian J. Pharm. Sci., in press, https://doi.org/10.1016/j.ajps.2023.100778.
[157]
Lee, Y.; Ha, J.; Kim, M.; Kang, S. B.; Kang, M. J.; Lee, M. Antisense-oligonucleotide co-micelles with tumor targeting peptides elicit therapeutic effects by inhibiting microRNA-21 in the glioblastoma animal models. J. Adv. Res., in press, https://doi.org/10.1016/J.JARE.2023.01.005.
[158]

Saini, S.; Sharma, T.; Jain, A.; Kaur, H.; Katare, O. P.; Singh, B. Systematically designed chitosan-coated solid lipid nanoparticles of ferulic acid for effective management of Alzheimer’s disease: A preclinical evidence. Colloids Surf. B: Biointerf. 2021, 205, 111838.
DOI Google Scholar
[159]

Zhou, C.; Sun, P.; Xu, Y.; Chen, Y. A.; Huang, Y. X.; Hamblin, M. H.; Foley, L.; Hitchens, T. K.; Li, S.; Yin, K. J. Genetic deficiency of microRNA-15a/16-1 confers resistance to neuropathological damage and cognitive dysfunction in experimental vascular cognitive impairment and dementia. Adv. Sci. (Weinh.) 2022, 9, 2104986.
DOI Google Scholar
[160]

Zhuang, X. Y.; Teng, Y.; Samykutty, A.; Mu, J. Y.; Deng, Z. B.; Zhang, L. F.; Cao, P. X.; Rong, Y.; Yan, J.; Miller, D. et al. Grapefruit-derived nanovectors delivering therapeutic miR17 through an intranasal route inhibit brain tumor progression. Mol. Ther. 2016, 24, 96–105.
DOI Google Scholar
[161]

Khan, A.; Aqil, M.; Imam, S. S.; Ahad, A.; Sultana, Y.; Ali, A.; Khan, K. Temozolomide loaded nano lipid based chitosan hydrogel for nose to brain delivery: Characterization, nasal absorption, histopathology and cell line study. Int. J. Biol. Macromol. 2018, 116, 1260–1267.
DOI Google Scholar
[162]

Guo, S. W.; Perets, N.; Betzer, O.; Ben-Shaul, S.; Sheinin, A.; Michaelevski, I.; Popovtzer, R.; Offen, D.; Levenberg, S. Intranasal delivery of mesenchymal stem cell derived exosomes loaded with phosphatase and tensin homolog sirna repairs complete spinal cord injury. ACS Nano 2019, 13, 10015–10028.
DOI Google Scholar
[163]

Abdelmonem, R.; El-Enin, H. A. A.; Abdelkader, G.; Abdel-Hakeem, M. Formulation and characterization of lamotrigine nasal insert targeted brain for enhanced epilepsy treatment. Drug Deliv. 2023, 30, 2163321.
DOI Google Scholar
[164]

Singh, S. K.; Hidau, M. K.; Gautam, S.; Gupta, K.; Singh, K. P.; Singh, S. K.; Singh, S. Glycol chitosan functionalized asenapine nanostructured lipid carriers for targeted brain delivery: Pharmacokinetic and teratogenic assessment. Int. J. Biol. Macromol. 2018, 108, 1092–1100.
DOI Google Scholar
[165]

Zafar, A.; Alsaidan, O. A.; Alruwaili, N. K.; Imam, S. S.; Yasir, M.; Alharbi, K. S.; Singh, L.; Ahmed, M. M. Formulation of intranasal surface engineered nanostructured lipid carriers of rotigotine: Full factorial design optimization, in vitro characterization, and pharmacokinetic evaluation. Int. J. Pharm. 2022, 627, 122232.
DOI Google Scholar
[166]

Noorulla, K. M.; Yasir, M.; Muzaffar, F.; Roshan, S.; Ghoneim, M. M.; Almurshedi, A. S.; Tura, A. J.; Alshehri, S.; Gebissa, T.; Mekit, S. et al. Intranasal delivery of chitosan decorated nanostructured lipid carriers of Buspirone for brain targeting: Formulation development, optimization and in-vivo preclinical evaluation. J. Drug Deliv. Sci. Technol. 2022, 67, 102939.
DOI Google Scholar
[167]

See, G. L.; Arce, F.; Dahlizar, S.; Okada, A.; Fadli, M. F. B. M.; Hijikuro, I.; Itakura, S.; Katakura, M.; Todo, H.; Sugibayashi, K. Enhanced nose-to-brain delivery of tranilast using liquid crystal formulations. J. Control. Release 2020, 325, 1–9.
DOI Google Scholar
[168]

García-Pardo, J.; Novio, F.; Nador, F.; Cavaliere, I.; Suárez-García, S.; Lope-Piedrafita, S.; Candiota, A. P.; Romero-Gimenez, J.; Rodríguez-Galván, B.; Bové, J. et al. Bioinspired theranostic coordination polymer nanoparticles for intranasal dopamine replacement in Parkinson’s disease. ACS Nano 2021, 15, 8592–8609.
DOI Google Scholar
[169]

Gadhave, D.; Rasal, N.; Sonawane, R.; Sekar, M.; Kokare, C. Nose-to-brain delivery of teriflunomide-loaded lipid-based carbopol-gellan gum nanogel for glioma: Pharmacological and in vitro cytotoxicity studies. Int. J. Biol. Macromol. 2021, 167, 906–920.
DOI Google Scholar
[170]

Gieszinger, P.; Csaba, N. S.; Garcia-Fuentes, M.; Prasanna, M.; Gáspár, R.; Sztojkov-Ivanov, A.; Ducza, E.; Márki, Á.; Janáky, T.; Kecskeméti, G. et al. Preparation and characterization of lamotrigine containing nanocapsules for nasal administration. Eur. J. Pharm. Biopharm. 2020, 153, 177–186.
DOI Google Scholar
[171]

Bhattamisra, S. K.; Shak, A. T.; Xi, L. W.; Safian, N. H.; Choudhury, H.; Lim, W. M.; Shahzad, N.; Alhakamy, N. A.; Anwer, M. K.; Radhakrishnan, A. K. et al. Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson’s disease. Int. J. Pharm. 2020, 579, 119148.
DOI Google Scholar
[172]

Nakao, Y.; Horiguchi, M.; Nakamura, R.; Sasaki-Hamada, S.; Ozawa, C.; Funane, T.; Ozawa, R.; Oka, J. I.; Yamashita, C. LARETH-25 and β-CD improve central transitivity and central pharmacological effect of the GLP-2 peptide. Int. J. Pharm. 2016, 515, 37–45.
DOI Google Scholar
[173]

Al-Suhaimi, E. A.; Nawaz, M.; Khan, F. A.; Aljafary, M. A.; Baykal, A.; Homeida, A. M. Emerging trends in the delivery of nanoformulated oxytocin across blood-brain barrier. Int. J. Pharm. 2021, 609, 121141.
DOI Google Scholar
[174]

Borrajo, M. L.; Alonso, M. J. Using nanotechnology to deliver biomolecules from nose to brain—peptides, proteins, monoclonal antibodies and RNA. Drug Deliv. Transl. Res. 2022, 12, 862–880.
DOI Google Scholar
[175]

Sharma, M.; Waghela, S.; Mhatre, R.; Saraogi, G. K. A recent update on intranasal delivery of high molecular weight proteins, peptides, and hormones. Curr. Pharm. Des. 2021, 27, 4279–4299.
DOI Google Scholar
[176]

González, L. F.; Acuña, E.; Arellano, G.; Morales, P.; Sotomayor, P.; Oyarzun-Ampuero, F.; Naves, R. Intranasal delivery of interferon-β-loaded nanoparticles induces control of neuroinflammation in a preclinical model of multiple sclerosis: A promising simple, effective, non-invasive, and low-cost therapy. J. Control. Release 2021, 331, 443–459.
DOI Google Scholar
[177]

Zhao, Y. Z.; Lin, M.; Lin, Q.; Yang, W.; Yu, X. C.; Tian, F. R.; Mao, K. L.; Yang, J. J.; Lu, C. T.; Wong, H. L. Intranasal delivery of bFGF with nanoliposomes enhances in vivo neuroprotection and neural injury recovery in a rodent stroke model. J. Control. Release 2016, 224, 165–175.
DOI Google Scholar
[178]

Zhou, X.; Deng, X. H.; Liu, M. F.; He, M. T.; Long, W. H.; Xu, Z. B.; Zhang, K.; Liu, T.; So, K. F.; Fu, Q. L. et al. Intranasal delivery of BDNF-loaded small extracellular vesicles for cerebral ischemia therapy. J. Control. Release 2023, 357, 1–19.
DOI Google Scholar
[179]

Bernocchi, B.; Carpentier, R.; Lantier, I.; Ducournau, C.; Dimier-Poisson, I.; Betbeder, D. Mechanisms allowing protein delivery in nasal mucosa using NPL nanoparticles. J. Control. Release 2016, 232, 42–50.
DOI Google Scholar
[180]

Henninger, N.; Mayasi, Y. Nucleic acid therapies for ischemic stroke. Neurotherapeutics 2019, 16, 299–313.
DOI Google Scholar
[181]

Shah, P.; Lalan, M.; Barve, K. Intranasal delivery: An attractive route for the administration of nucleic acid based therapeutics for CNS disorders. Front Pharmacol. 2022, 13, 974666.
DOI Google Scholar
[182]

Rupaimoole, R.; Slack, F. J. MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Discov. 2017, 16, 203–222.
DOI Google Scholar
[183]

Zheng, T.; Wang, W. T.; Mohammadniaei, M.; Ashley, J.; Zhang, M.; Zhou, N. L.; Shen, J.; Sun, Y. Anti-microRNA-21 oligonucleotide loaded spermine-modified acetalated dextran nanoparticles for B1 receptor-targeted gene therapy and antiangiogenesis therapy. Adv. Sci. (Weinh.) 2022, 9, 2103812.
DOI Google Scholar
[184]

Lee, Y.; Kim, M.; Ha, J.; Lee, M. Brain-targeted exosome-mimetic cell membrane nanovesicles with therapeutic oligonucleotides elicit anti-tumor effects in glioblastoma animal models. Bioeng. Transl. Med. 2023, 8, e10426.
DOI Google Scholar
[185]

Ha, J.; Kim, M.; Lee, Y.; Lee, M. Intranasal delivery of self-assembled nanoparticles of therapeutic peptides and antagomirs elicits anti-tumor effects in an intracranial glioblastoma model. Nanoscale 2021, 13, 14745–14759.
DOI Google Scholar
[186]

Kim, M.; Lee, Y.; Lee, M. Hypoxia-specific anti-RAGE exosomes for nose-to-brain delivery of anti-miR-181a oligonucleotide in an ischemic stroke model. Nanoscale 2021, 13, 14166–14178.
DOI Google Scholar
[187]

Dong, Y. Z.; Siegwart, D. J.; Anderson, D. G. Strategies, design, and chemistry in siRNA delivery systems. Adv. Drug Deliv. Rev. 2019, 144, 133–147.
DOI Google Scholar
[188]

Whitehead, K. A.; Langer, R.; Anderson, D. G. Knocking down barriers: Advances in siRNA delivery. Nat. Rev. Drug Discov. 2009, 8, 129–138.
DOI Google Scholar
[189]

Tang, L.; Zhang, R.; Wang, Y. S.; Zhang, X. Y.; Yang, Y. L.; Zhao, B. Y.; Yang, L. A simple self-assembly nanomicelle based on brain tumor-targeting peptide-mediated siRNA delivery for glioma immunotherapy via intranasal administration. Acta Biomater. 2023, 155, 521–537.
DOI Google Scholar
[190]

Yang, Y. L.; Zhang, X. Y.; Wu, S. W.; Zhang, R.; Zhou, B. L.; Zhang, X. Y.; Tang, L.; Tian, Y. M.; Men, K.; Yang, L. Enhanced nose-to-brain delivery of siRNA using hyaluronan-enveloped nanomicelles for glioma therapy. J. Control. Release 2022, 342, 66–80.
DOI Google Scholar
[191]

Yang, X. T.; Yang, W. Q.; Xia, X.; Lei, T.; Yang, Z. H.; Jia, W. F.; Zhou, Y.; Cheng, G.; Gao, H. L. Intranasal delivery of BACE1 siRNA and rapamycin by dual targets modified nanoparticles for Alzheimer’s disease therapy. Small 2022, 18, 2203182.
DOI Google Scholar
[192]

Aly, A. E. E.; Harmon, B. T.; Padegimas, L.; Sesenoglu-Laird, O.; Cooper, M. J.; Waszczak, B. L. Intranasal delivery of pGDNF DNA nanoparticles provides neuroprotection in the rat 6-hydroxydopamine model of Parkinson’s disease. Mol. Neurobiol. 2019, 56, 688–701.
DOI Google Scholar
[193]

Aly, A. E. E.; Harmon, B.; Padegimas, L.; Sesenoglu-Laird, O.; Cooper, M. J.; Yurek, D. M.; Waszczak, B. L. Intranasal delivery of hGDNF plasmid DNA nanoparticles results in long-term and widespread transfection of perivascular cells in rat brain. Nanomed. Nanotechnol. Biol. Med. 2019, 16, 20–33.
DOI Google Scholar
[194]

Shin, H.; Park, S. J.; Yim, Y.; Kim, J.; Choi, C.; Won, C.; Min, D. H. Recent advances in RNA therapeutics and RNA delivery systems based on nanoparticles. Adv. Therap. 2018, 1, 1800065.
DOI Google Scholar
[195]

Xiao, X. R.; Li, H.; Zhao, L. J.; Zhang, Y. F.; Liu, Z. C. Oligonucleotide aptamers: Recent advances in their screening, molecular conformation and therapeutic applications. Biomed. Pharmacother. 2021, 143, 112232.
DOI Google Scholar
[196]

Bukari, B.; Samarasinghe, R. M.; Noibanchong, J.; Shigdar, S. L. Non-invasive delivery of therapeutics into the brain: The potential of aptamers for targeted delivery. Biomedicines 2020, 8, 120.
DOI Google Scholar
[197]

Elnaggar, Y. S. R.; Etman, S. M.; Abdelmonsif, D. A.; Abdallah, O. Y. Intranasal piperine-loaded chitosan nanoparticles as brain-targeted therapy in Alzheimer’s disease: Optimization, biological efficacy, and potential toxicity. J. Pharm. Sci. 2015, 104, 3544–3556.
DOI Google Scholar
[198]

Don, T. M.; Chang, W. J.; Jheng, P. R.; Huang, Y. C.; Chuang, E. Y. Curcumin-laden dual-targeting fucoidan/chitosan nanocarriers for inhibiting brain inflammation via intranasal delivery. Int. J. Biol. Macromol. 2021, 181, 835–846.
DOI Google Scholar
[199]

Tang, S. N.; Wang, A. P.; Yan, X. J.; Chu, L. X.; Yang, X. C.; Song, Y. N.; Sun, K. X.; Yu, X.; Liu, R. X.; Wu, Z. M. et al. Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson’s disease. Drug Deliv. 2019, 26, 700–707.
DOI Google Scholar
[200]

Rassu, G.; Porcu, E. P.; Fancello, S.; Obinu, A.; Senes, N.; Galleri, G.; Migheli, R.; Gavini, E.; Giunchedi, P. Intranasal delivery of genistein-loaded nanoparticles as a potential preventive system against neurodegenerative disorders. Pharmaceutics 2018, 11, 8.
DOI Google Scholar
[201]

Fonseca-Santos, B.; Chorilli, M. The uses of resveratrol for neurological diseases treatment and insights for nanotechnology based-drug delivery systems. Int. J. Pharm. 2020, 589, 119832.
DOI Google Scholar
[202]

Wang, H.; Zheng, Y.; Sun, Q.; Zhang, Z.; Zhao, M. N.; Peng, C.; Shi, S. J. Ginsenosides emerging as both bifunctional drugs and nanocarriers for enhanced antitumor therapies. J. Nanobiotechnol. 2021, 19, 322.
DOI Google Scholar
[203]

Karthika, C.; Appu, A. P.; Akter, R.; Rahman, M. H.; Tagde, P.; Ashraf, G. M.; Abdel-Daim, M. M.; Ul Hassan, S. S.; Abid, A.; Bungau, S. Potential innovation against Alzheimer’s disorder: A tricomponent combination of natural antioxidants (vitamin E, quercetin, and basil oil) and the development of its intranasal delivery. Environ. Sci. Pollut. Res. 2022, 29, 10950–10965.
DOI Google Scholar
[204]

Bandiwadekar, A.; Jose, J.; Khayatkashani, M.; Habtemariam, S.; Kashani, H. R. K.; Nabavi, S. M. Emerging novel approaches for the enhanced delivery of natural products for the management of neurodegenerative diseases. J. Mol. Neurosci. 2022, 72, 653–676.
DOI Google Scholar
[205]

Xu, D.; Lu, Y. R.; Kou, N.; Hu, M. J.; Wang, Q. S.; Cui, Y. L. Intranasal delivery of icariin via a nanogel-thermoresponsive hydrogel compound system to improve its antidepressant-like activity. Int. J. Pharm. 2020, 586, 119550.
DOI Google Scholar
[206]

Xu, D.; Qiao, T.; Wang, Y.; Wang, Q. S.; Cui, Y. L. Alginate nanogels-based thermosensitive hydrogel to improve antidepressant-like effects of albiflorin via intranasal delivery. Drug Deliv. 2021, 28, 2137–2149.
DOI Google Scholar
[207]

Qizilbash, F. F.; Ashhar, M. U.; Zafar, A.; Qamar, Z.; Annu; Ali, J.; Baboota, S.; Ghoneim, M. M.; Alshehri, S.; Ali, A. Thymoquinone-enriched naringenin-loaded nanostructured lipid carrier for brain delivery via nasal route: In vitro prospect and in vivo therapeutic efficacy for the treatment of depression. Pharmaceutics 2022, 14, 656.
DOI Google Scholar
[208]

Dou, Y.; Zhao, D. J.; Yang, F.; Tang, Y. Q.; Chang, J. Natural phyto-antioxidant albumin nanoagents to treat advanced Alzheimer’s disease. ACS Appl. Mater. Interfaces 2021, 13, 30373–30382.
DOI Google Scholar
[209]

Wang, L. T.; Xu, L.; Du, J. F.; Zhao, X.; Liu, M.; Feng, J. F.; Hu, K. L. Nose-to-brain delivery of borneol modified tanshinone IIA nanoparticles in prevention of cerebral ischemia/reperfusion injury. Drug Deliv. 2021, 28, 1363–1375.
DOI Google Scholar
[210]

Ali, J.; Ali, M.; Baboota, S.; Sahni, J. K.; Ramassamy, C.; Dao, L.; Bhavna. Potential of nanoparticulate drug delivery systems by intranasal administration. Curr. Pharm. Des. 2010, 16, 1644–1653.
DOI Google Scholar
[211]
Shahi, S. R.; Pardeshi, C. V. Chapter 21—A technology overview on advanced drug administration devices for effective nose-to-brain delivery. In Direct Nose-to-Brain Drug Delivery. Pardeshi, C. V.; Souto, E. B., Eds.; Academic Press, 2021; pp 417–427.
Publication history
Copyright
Acknowledgements

Publication history

Received: 10 May 2023
Revised: 18 July 2023
Accepted: 20 July 2023
Published: 12 October 2023
Issue date: December 2023

Copyright

© Tsinghua University Press 2023

Acknowledgements

Acknowledgements

This work was financially supported by the STI 2030-Major Projects (No. 2021ZD0201602).

Return